Active Biotech AB Interim Report January-June 2006
LUND, SWEDEN -- (MARKET WIRE) -- August 10, 2006 --
* Final report from Phase II study of laquinimod to be presented before year-end
* ANYARA Phase II/III renal cancer study to start in Q4
* Recruitment for Phase I TASQ study completed; evaluation scheduled for Q3
* Preclinical data for 57-57 supports ongoing clinical development
* Net sales: SEK 11.4 million (5.8)
* Operating loss: SEK 79.3 million (loss: 100.5)
* Loss after tax: SEK 83.4 million (loss: 110.3)
* Loss per share for the period: SEK 2.10 (loss: 3.18)